Pathophysiology: Heart Failure. Objectives

Similar documents
Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies

Pathophysiology: Heart Failure

Pathophysiology: Heart Failure. Objectives

Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy

Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output

Definition of Congestive Heart Failure

Improving Transition of Care in Congestive Heart Failure. Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare

Heart Failure (HF) Treatment

In Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Heart Failure Dr ahmed almutairi Assistant professor internal medicin dept

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions.

Review of Cardiac Mechanics & Pharmacology 10/23/2016. Brent Dunworth, CRNA, MSN, MBA 1. Learning Objectives

Diastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

Pre-discussion questions

Congestive Heart Failure Patient Profile. Patient Identity - Mr. Douglas - 72 year old man - No drugs, smokes, moderate social alcohol consumption

Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF

HFpEF. April 26, 2018

Topic Page: congestive heart failure

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.

Circulation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.

Cardiac Output MCQ. Professor of Cardiovascular Physiology. Cairo University 2007

Ejection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.

Diagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta

Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation

A Guide to the Etiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure. Part I: Etiology and Pathophysiology of Heart Failure

Heart Failure. Dr. William Vosik. January, 2012

Definition: A state in which the heart cannot provide sufficient cardiac output to satisfy the metabolic needs of the body

Incidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction

The Failing Heart in Primary Care

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

CHF is a clinical syndrome in which heart failure is accompanied by symptoms and signs of pulmonary and/or peripheral congestion

M2 TEACHING UNDERSTANDING PHARMACOLOGY

Innovation therapy in Heart Failure

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year

Heart Failure Overview. Dr Chris K Y Wong

Advanced Care for Decompensated Heart Failure

CARDIOGENIC SHOCK. Antonio Pesenti. Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI)

Presenter: Steven Brust, HCS-D, HCS-H Product Manager, Home Health Coding Center

Advanced Pathophysiology Unit 5 CV Page 1 of 24. Learning Objectives:

Summary/Key Points Introduction

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

Cardiac Output (C.O.) Regulation of Cardiac Output

LXIV: DRUGS: 4. RAS BLOCKADE

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

The Causes of Heart Failure

Etiology, Classification & Management. Sheba Medical Center Cardiology Department Matthew Wright St. George s University of London

Cardiomyopathy. Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement

Dysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias

4/11/2017. Cardiomyopathy. John Steuter, MD Bryan Heart. Disclosures. No Conflicts. Cardiomyopathy. WHO Classification

Heart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic

DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE

Peripartum Cardiomyopathy. Lavanya Rai Manipal

The right heart: the Cinderella of heart failure

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid

THE CARDIOVASCULAR SYSTEM

Drugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia

HEART FAILURE. Study day November 2018 Sarah Briggs

Congestive Heart Failure: Outpatient Management

Our Readers Have An Attitude Toward Living

Heart Failure Overview. Dr Chris K Y Wong

For more information about how to cite these materials visit

5 Important Things to Know About Heart Failure. Kia Afshar, MD

SPECIAL PATHOPHYSIOLOGY CARDIO-VASCULAR SYSTEM

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

Akash Ghai MD, FACC February 27, No Disclosures

State-of-the-Art Management of Chronic Systolic Heart Failure

CKD Satellite Symposium

DOWNLOAD PDF ABC OF HEART FAILURE

LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital

Heart 101. Objectives. Types of Heart Failure How common is HF? Sign/Symptoms, when to see a doctor? Diagnostic testing

Intravenous Inotropic Support an Overview

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition

Left ventricular hypertrophy: why does it happen?

For more information about how to cite these materials visit

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Updates in Diagnosis & Management of CHF

During exercise the heart rate is 190 bpm and the stroke volume is 115 ml/beat. What is the cardiac output?

Age-related changes in cardiovascular system. Dr. Rehab Gwada

Antialdosterone treatment in heart failure

Failing Heart. Cardiac Resynchronization: novel therapy for the

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Assessment and Diagnosis of Heart Failure

Cor pulmonale. Dr hamid reza javadi

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

Lnformation Coverage Guidance

Heart Failure CTSHP Fall Seminar

Management Strategies for Advanced Heart Failure

2016 Update to Heart Failure Clinical Practice Guidelines

Nothing to Disclose. Severe Pulmonary Hypertension

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Pulmonary Hypertension: Another Use for Viagra

RV dysfunction and failure PATHOPHYSIOLOGY. Adam Torbicki MD, Dept Chest Medicine Institute of Tuberculosis and Lung Diseases Warszawa, Poland

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment

Heart Failure: Combination Treatment Strategies

I have no disclosures. Disclosures

Transcription:

Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Clinical Medicine Objectives At the conclusion of this seminar, learner will be able to: 1. Define heart failure as a clinical syndrome 2. Define and employ the terms preload, afterload, contractilty, remodeling, diastolic dysfunction, compliance, stiffness and capacitance. 3. Describe the classic pathophysiologic steps in the development of heart failure: insult/injury/remodeling stimuli neurohormonal activation (RAAS and ANS) cellular/molecular alterations, hemodynamic alterations (Na retention, volume overload) Remodeling Morbidity and mortality 4. Delineate four basic mechanisms underlying the development of heart failure 5. Interpret pressure volume loops / Starling curves and identify contributing mechanisms for heart failure state. 6. Understand the common methods employed for classifying patients with heart failure. 7. Employ the classes and stages of heart failure in describing a clinical scenario 1

Outline Definitions and Classifications Muscle and Chamber Function Pathophysiology Epidemiology Clinical Management Heart Failure: Definitions An inability of the heart to pump blood at a sufficient rate to meet the metabolic demands of the body (e.g. oxygen and cell nutrients) at rest and during effort or to do so only if the cardiac filling pressures are abnormally high. A complex clinical syndrome characterized by abnormalities in cardiac function and neurohormonal regulation, which are accompanied by effort intolerance, fluid retention and a reduced longevity A complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. 2

Heart Failure Not a disease A syndrome From "syn meaning "together and "dromos" meaning "a running. A group of signs and symptoms that occur together and characterize a particular abnormality. Diverse etiologies Several mechanisms Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrcitive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output 3

Heart Failure Paradigms Epidemiology Heart Failure: The Problem Heart Failure Patients in the US (Millions) 12 10 8 6 4 2 0 1991 2000 2037 3.5 million in 1991, 4.7 million in 2000, estimated 10 million in 2037 Incidence: 550,000 new cases/year Prevalence: 1% ages 50--59, >10% over age 80 More deaths from HF than from all forms of cancer combined Most common cause for hospitalization in age >65 4

Cardiac Muscle Function Preload Afterload Contractility Tension (g) d b a c Muscle Length (mm) Tension (g) L c e L a a c Muscle Length (mm) Tension (g) +norepinephrine f b g e a Muscle Length (mm) The length of a cardiac muscle fiber prior to the onset of contraction. Frank Starling The force against which a cardiac muscle fiber must shorten. Isotonic Contraction The force of contraction independent of preload and afterload. Inotropic State From Muscle to Chamber 5

The Pressure Volume Loop Diastole Systole The Pressure Volume Loop P es Pressure ESPVR Preload Preload EDPVR Volume 6

Compliance/Stiffness vs Capacitance 25 LV Pressure (mmhg) 20 15 10 5 0-5 Capacitance = volume at specified pressure EDPVR 20 40 60 80 100 120 140 LV Volume (ml) Slope = stiffness = 1/compliance LV Pressure (mmhg) 50 40 30 20 10 Diastolic Dysfunciton Normal Remodeling 0 0 50 100 150 200 250 LV Volume (ml) Cardiac Chamber Function Preload Afterload Contractility EDV EDP Wall stress at end diastole Aortic Pressure Total peripheral resistance Arterial impedance Wall stress at end systole Pressure generated at given volume. Inotropic State 7

Frank Starling Curves Hypotension Pulmonary Congestion Pathophysiology - PV Loop 8

Pathophysiology of Heart Failure Myocardial Insult/Stimuli/Damage Pump dysfunction Activation of neurohormones Catecholamines Angiontensin II Cytokines Remodeling Hypertrophy Fibrosis Apoptosis Neurohormonal Activation in Heart Failure Myocardial injury to the heart (CAD, HTN, CMP, valvular disease) Initial fall in LV performance, wall stress Activation of RAS and SNS Remodeling and progressive worsening of LV function Morbidity and mortality Arrhythmias Pump failure RAS, renin-angiotensin system; SNS, sympathetic nervous system. Fibrosis, apoptosis, hypertrophy, cellular/molecular alterations, myotoxicity Peripheral vasoconstriction Sodium retention Hemodynamic alterations Heart failure symptoms Fatigue Activity altered Chest congestion Edema Shortness of breath 9

Neurohormonal Activation in Heart Failure Angiotensin II Norepinephrine Hypertrophy, apoptosis, ischemia, arrhythmias, remodeling, fibrosis Morbidity and Mortality Adrenergic Pathway in Heart Failure Progression CNS sympathetic outflow Cardiac sympathetic activity Vascular sympathetic activity Renal sympathetic activity 1 2 1 1 1 1 Myocyte hypertrophy Myocyte injury Increased arrhythmias Vasoconstriction Activation of RAS Sodium retention Disease progression 10

Neurohormonal Balance in Heart Failure Neurohormones in Heart Failure Myocardial Injury Fall in LV Performance Activation of RAAS and SNS (endothelin, AVP, cytokines) Myocardial Toxicity Change in Gene Expression ANP BNP Peripheral Vasoconstriction Sodium/Water Retention Morbidity and Mortality Remodeling and Progressive Worsening of LV Function HF Symptoms Shah M et al. Rev Cardiovasc Med. 2001;2(suppl 2):S2 11

Pathophyisiology of myocardial remodeling: Insult / Remodeling Stimuli Wall Stress Cytokines Neurohormones Oxidative stress Increased Wall Stress Myocyte Hypertrophy Altered interstitial matrix Fetal Gene Expression Altered calcium handling proteins Myocyte Death Ventricular Enlargement Diastolic Dysfunction Systolic Dysfunction Response Salt and water retention Acute and Chronic Responses Benefits and Harm Short-term Effects (mainly adaptive; hemorrhage, acute heart failure) Augments preload Long-term Effects (mainly deleterious; chronic heart failure) Pulmonary congestion, anasarca Vasoconstriction Maintains pressure for perfusion of vital organs (brain, heart) Exacerbates pump dysfunction, increases cardiac energy expenditure Sympathetic stimulation Cytokine activation Hypertrophy Increased collagen Increases heart rate and ejection Vasodilatation Unloads individual muscle fibers May reduce dilatation Increases energy expenditure Skeletal muscle catabolism, deterioration of endothelial function, impaired contraction, LV remodeling. Deterioration and death of cardiac cells: cardiomyopathy of overload Impairs relaxation 12

Laplace s Law Where P = ventricular pressure, r = ventricular chamber radius and h = ventricular wall thickness Remodeling Concentric vs. Eccentric 13

Ventricular Remodeling Pathophysiology of Heart Failure Four Basic Mechanisms 1. Increased Blood Volume (Excessive Preload) 2. Increased Resistant to Blood Flow (Excessive Afterload) 3. Decreased contractility 4. Decreased Filling 14

Aortic Regurgitation Increased Blood Volume AI + Remodeling AI + HF Ventricular Remodeling Na Retention Vasoconstriction Etiologies Mitral Regurgitation Aortic Regurgitation Volume Overload Left to Right Shunts Chronic Kidney Disease Parameter BP (mm Hg) SV (ml) Cardiac Output (L/min) Normal 140/75 64 3.8 AI 128/50 80 3.0 AI + Remodeling 85/35 54 2.1 AI + Heart failure 104/45 63 2.6 PCWP (mm Hg) 10 13 13 20 Hypertension Increased Afterload HTN + DD HTN + DD + HF Diastolic Dysfunction Na Retention Vasoconstriction Remodeling Etiologies Aortic Stenosis Aortic Coarctation Hypertension Parameter BP (mm Hg) SV (ml) Cardiac Output (L/min) Normal 124/81 61 3.7 HTN 159/122 51 3.1 HTN + DD 170/129 54 3.2 HTN + Heart failure 206/159 65 3.9 PCWP (mm Hg) 10 10 12 21 15

MI Decreased Contractility MI + Remodeling MI + Heart Failure Ventricular Remodeling Na Retention Vasoconstriction Etiologies Ischemic Cardiomyopathy MI + MI + Myocardial Infarction Parameter Normal MI Remodeling HF Myocardial Ischemia Myocarditis Toxins BP (mm Hg) SV (ml) 124/81 61 68/46 35 68/45 34 80/50 38 Anthracycline Cardiac Output (L/min) 3.7 2.1 2.0 2.3 Alcohol Cocaine PCWP (mm Hg) 10 16 33 18 Normal Decreased Filling HCM HCM + HF Ventricular Remodeling Na Retention Vasoconstriction Etiologies Mitral Stenosis Constriction Restrictive Cardiomypoathy Cardiac Tamponade Hypertrophic Cardiomyopathy Infiltrative Cardiomyopathy Parameter BP (mm Hg) SV (ml) Cardiac Output (L/min) PCWP (mm Hg) Normal 124/81 61 3.7 10 HCM 112/74 57 3.4 12 HCM + HF 131/87 66 4.0 27 16

Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrcitive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output Types of Heart Failure SHF Diastolic Pathophysiology Demographics 1 Cause Impaired Contraction All ages Coronary Artery Disease Impaired filling > 60 years Hypertension 17

Systolic Versus Diastolic Failure Systolic Dysfunction Contractility Normal Diastolic Dysfunction Pressure Pressure Pressure Capacitance Volume Volume Volume Systolic Versus Diastolic Failure 18

Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrcitive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output Decompensated Heart Failure 19

Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrictive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output High vs. Low Output Failure Causes: Anemia Systemic arteriovenous fistulas Hyperthyroidism Beriberi heart disease Paget disease of bone Glomerulonephritis Polycythemia vera Carcinoid syndrome Obesity Anemia Multiple myeloma Pregnancy Cor pulmonale Polycythemia vera 20

Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrictive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output Dilated vs. Hypertrophic vs. Restrictive Type Dilated Hypertrophic Restrictive Definition Dilated left/both ventricle(s) with impaired contraction Left and/or right ventricular hypertrophy Restrictive filling and reduced diastolic filling of one/both ventricles, Normal/near normal systolic function Sample Etiologies Ischemic, idiopathic, familial, viral, alcoholic, toxic, valvular Familial with autosomal dominant inheritance Idiopathic, amyloidosis, endomyocardial fibrosis 21

Dilated vs. Hypertrophic vs. Restrictive Clinical Manifestations Symptoms Reduced exercise tolerance Shortness of breath Congestion Fluid retention Difficulty in sleeping Weight loss 22

Diagnosis of heart failure Physical examination Chest X ray EKG Echocardiogram Blood tests: Na, BUN, Creatinine, BNP Exercise test MRI Cardiac catheterization NYHA Classification I II III IV Class Mild Mild Moderate Severe Patient Symptoms No limitation of physical activity No undue fatigue, palpitation or dyspnea Slight limitation of physical activity Comfortable at rest Less than ordinary activity results in fatigue, palpitation, or dyspnea Marked limitation of physical activity Comfortable at rest Less than ordinary activity results in fatigue, palpitation, or dyspnea Unable to carry out any physical activity without discomfort Symptoms of cardiac insufficiency at rest Physical activity causes increased discomfort 23

ACC/AHA Staging System STAGE A High risk for developing HF STAGE B Asymptomatic LV dysfunction STAGE C Past or current symptoms of HF STAGE D End-stage HF Hunt, et al. J Am Coll Cardiol. 2001; 38:2101-2113. ACC/AHA Staging System A B C D Stage High risk for developing heart failure Asymptomatic heart failure Symptomatic heart failure Refractory end-stage heart failure Patient Description Hypertension Coronary artery disease Diabetes mellitus Family history of cardiomyopathy Previous myocardial infarction Left ventricular systolic dysfunction Asymptomatic valvular disease Known structural heart disease Shortness of breath and fatigue Reduced exercise tolerance Marked symptoms at rest despite maximal medical therapy (e.g., those who are recurrently hospitalized or cannot be safely discharged from the hospital without specialized interventions) 24

Goals of Treatment 1. Identification and correction of underlying condition causing heart failure. 2. Elimination of acute precipitating cause of symptoms. 3. Modulation of neurohormonal response to prevent progression of disease. 4. Improve long term survival. Etiologies Ischemic cardiomyopathy Valvular cardiomyopathy Hypertensive cardiomyopathy. Inflammatory cardiomyopathy Metabolic cardiomyopathy General system disease Muscular dystrophies. Neuromuscular disorders. Sensitivity and toxic reactions. Peripartal cardiomyopathy 25

Percipients /Associated Factors Inappropriate reduction in the intensity of treatment, including Dietary sodium restriction, Physical activity reduction, Drug regimen reduction, or, most commonly, a combination of these measures. Ischemia Hypertension Anemia Volume Overload Increased Metabolic Demand Infection Thyroid Disease Arrhythmia Asthma/COPD Targets of Treatment Standard Pharmacological Therapy ACE inhibitors Angiotensin Receptor Blockers Beta Blcokers Diuretics Aldosterone Antagonists Statins Vasodilators Inotropes 26

Treatment A B C D Stage High risk for developing heart failure Asymptomatic heart failure Symptomatic heart failure Refractory end-stage heart failure Patient Treatment Hypertension Optimal pharmacologic therapy (OPT) Coronary artery disease Diabetes mellitus Family history of cardiomyopathy OPT Previous myocardial infarction Left ventricular systolic dysfunction present Asymptomatic valvular disease OPT Known structural heart disease Shortness of breath and fatigue CRT Reduced (if QRS exercise wide, LVEF 35%) tolerance Aspirin, ACE inhibitors, statins, b-blockers, a-b-blockers (carvedilol) diabetic therapy ICD if left ventricular (LV) dysfunction (systolic) ICD if LV dysfunction (systolic) present OPT Marked symptoms at rest despite maximal Intermittent medical therapy IV inotropes (e.g., those who are recurrently ICD hospitalized as a bridge or to cannot transplantation be safely discharged from CRT the hospital without specialized interventions) Other devices (LVAD, pericardial restraint) Treatment of Acute Heart Failure 27

ACC/AHA Staging System Summary Complex Clinical Syndrome Multiple Etiologies and Classification Systems Physiologic Understanding Essential http://www.columbia.edu/itc/hs/medical/heartsim/ 28

29